Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Eileen Mary O'Reilly, Devalingam Mahalingam, James M. Roach, Paul Justin Miller, Molly E. Rosano, Silva Krause, Julie Wolf, Keith Flaherty, David P. Ryan
Title Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-Paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Updated phase 1 results.
Journal J Clin Oncol
Abstract Text J Clin Oncol 34, 2016 (suppl; abstr 4117)


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown pancreatic cancer not applicable Gemcitabine + Nab-paclitaxel + Necuparanib Phase I Actionable In a Phase I trial, combination treatment consisted of Gemzar (gemcitabine), Abraxane (nab-paclitaxel), and Necuparanib resulted in partial response in 50% (8/16), stable disease in 38% (6/16), and median overall survival of 16.0 months in patients (pts) with metastatic pancreatic cancer (J Clin Oncol 34, 2016 (suppl; abstr 4117)). detail...